INVICTUS ANNOUNCES AB LABORATORIES INC. RECEIVES AMENDED LICENSE
11 September 2019 - 3:00PM
Vancouver, BC, September 11, 2019 - INVICTUS MD STRATEGIES CORP.
("Invictus" or the "Company") (TSXV: GENE; OTCQX: IVITF; FRA:
8IS2) is pleased to announce that AB Laboratories Inc. (“
AB
Labs”) a company which is a 50% owned subsidiary of Invictus
has received their amended license from Health Canada to include
the new 40,000 sq. ft. custom built cultivation facility located
near Hamilton, Ontario.
As previously announced on June 26, 2019, AB Labs’ facility
contains ten identical cultivation rooms capable of producing over
65 crops annually on a tightly controlled weekly production
schedule. Five rooms have been propagated since receiving the
amended license on August 30, 2019. The initial harvest is
scheduled for November 1, 2019. The remaining rooms are
expected to be propagated at a rate of one room per week over the
next five weeks to ensure a reliable continuous production of
cannabis for the recreational and medical markets.
Mr. Marc Ripa, Chief Operating Officer of Invictus and Chief
Executive Officer of AB Labs and the other 50% owner of AB Labs
stated, “AB Labs submitted the evidence package on June 4, 2019 and
received the amended license from Health Canada in less than ninety
days. I am extremely pleased with the efficiency of
Health Canada in processing AB Labs’ documentation. The
employees have been working extremely hard since receipt of the
license to get the five rooms into production and are continuing to
press on with the additional five rooms.”
Mr. Trevor Dixon, President and CEO of the Company said, “The
completion of these ten rooms will double the Company’s volume of
finished product going to market this year”.
For more information, please visit www.invictus-md.com.
Trevor Dixon
Chief Executive Officer
Investor Relations 1-844-800-6086
E-Mail: connect@invictus-md.com
Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
About Invictus
Invictus is a global cannabis company with a focus on the
Canadian cannabis space, offering a selection of products under a
wide range of cannabinoid profiles that fit the demand of the
Company’s medical clients and retail customers. The Company’s
integrated sales approach is defined by five pillars of
distribution including medical, adult-use, international, Licensed
Producer to Licensed Producer and sales to provinces.
To meet growing demand, Invictus is expanding its cultivation
footprint with two cannabis production facilities licensed under
the Cannabis Act, which replaced the Access to Cannabis for Medical
Purposes Regulations in Canada. Invictus’ wholly-owned subsidiary
Acreage Pharms Ltd.’s (“Acreage”) Phase I and Phase II
facilities are in full production. Acreage is awaiting the
amendment to their license from Health Canada to include the Phase
III facility. AB Laboratories Inc., a company which is a 50% owned
subsidiary of Invictus has completed it Phase II expansion and
received its amended license from Health Canada. Another of
Invictus’ wholly owned subsidiaries, 2015059 Alberta Ltd. (dba Leaf
Wise), continues to connect medical clients to physicians for
medical cannabis and to Invictus’ fully licensed cannabis producers
under the Cannabis Act. Future Harvest Development Ltd., a
company which is a 82.5% owned subsidiary of Invictus, continues to
produce high-quality fertilizer and nutrients. Invictus is
targeting up to 50 percent of production to medical cannabis.
Invictus drives sustainable long-term shareholder value by
continuing to develop Invictus’ Canadian production of medical and
recreational cannabis products. For more information visit
www.invictus-md.com.
Cautionary Note Regarding Forward-Looking Statements: This
release includes certain statements and information that may
constitute forward-looking information within the meaning of
applicable Canadian securities laws. All statements in this news
release, other than statements of historical facts, including
statements regarding the expectation that AB Labs’ new grow rooms
will be propagated at a rate of one room per week over the next
five weeks, is a forward-looking statement and contain
forward-looking information. Generally, forward-looking statements
and information can be identified by the use of forward-looking
terminology such as “intends” or “anticipates”, or variations of
such words and phrases or statements that certain actions, events
or results “may”, “could”, “should”, “would” or “occur”.
Forward-looking statements are based on certain material
assumptions and analysis made by the Company and the opinions and
estimates of management as of the date of this press release,
including that AB Labs’ new grow rooms will be propagated at a rate
of one room per week over the next five weeks. These
forward-looking statements are subject to known and unknown risks,
uncertainties and other factors that may cause the actual results,
level of activity, performance or achievements of the Company to be
materially different from those expressed or implied by such
forward-looking statements or forward-looking information.
Important factors that may cause actual results to vary, include,
without limitation, that AB Labs’ new grow rooms will not be
propagated at a rate of one room per week over the next five weeks
if at all. Although management of the Company has attempted to
identify important factors that could cause actual results to
differ materially from those contained in forward-looking
statements or forward-looking information, there may be other
factors that cause results not to be as anticipated, estimated or
intended. There can be no assurance that such statements will prove
to be accurate, as actual results and future events could differ
materially from those anticipated in such statements. Accordingly,
readers should not place undue reliance on forward-looking
statements and forward-looking information. Readers are cautioned
that reliance on such information may not be appropriate for other
purposes. The Company does not undertake to update any
forward-looking statement, forward-looking information or financial
out-look that are incorporated by reference herein, except in
accordance with applicable securities laws.
Kathy Love
Invictus
kathy@invictus-md.com
Invictus MD Strategies (TSXV:GENE)
Historical Stock Chart
Von Dez 2024 bis Jan 2025
Invictus MD Strategies (TSXV:GENE)
Historical Stock Chart
Von Jan 2024 bis Jan 2025